Cargando…

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates

Detalles Bibliográficos
Autores principales:	Wang, Yanming, Xiao, Dian, Li, Jiaguo, Fan, Shiyong, Xie, Fei, Zhong, Wu, Zhou, Xinbo, Li, Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776858/ https://www.ncbi.nlm.nih.gov/pubmed/35058439 http://dx.doi.org/10.1038/s41392-021-00833-8

Ejemplares similares

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

Antibody–drug conjugates: Recent advances in linker chemistry
por: Su, Zheng, et al.
Publicado: (2021)

Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety
por: Wang, Yanming, et al.
Publicado: (2020)

Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy
por: Wang, Yanming, et al.
Publicado: (2019)

Development of applicable thiol-linked antibody–drug conjugates with improved stability and therapeutic index
por: Wang, Yanming, et al.
Publicado: (2022)

Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023)

Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload
por: Wang, Yanming, et al.
Publicado: (2017)

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Glutathione S-conjugates as prodrugs to target drug-resistant tumors
por: Ramsay, Emma E., et al.
Publicado: (2014)

Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates
por: Liu, Lianqi, et al.
Publicado: (2021)

A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate
por: Xiao, Dian, et al.
Publicado: (2021)

Pro-Moieties of Antimicrobial Peptide Prodrugs
por: Forde, Eanna, et al.
Publicado: (2015)

Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302
por: Wojtkowiak, Jonathan W, et al.
Publicado: (2015)

Hypoxia-activated prodrugs and redox-responsive nanocarriers
por: Zeng, Yun, et al.
Publicado: (2018)

Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
por: Denny, William A.
Publicado: (2022)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Tetrazine-mediated bioorthogonal prodrug–prodrug activation
por: Neumann, Kevin, et al.
Publicado: (2018)

Prodrugs and prodrug-activated systems in gene therapy
por: Sheikh, Semira, et al.
Publicado: (2021)

Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors
por: Lindsay, Danika, et al.
Publicado: (2016)

Pro-senescence neddylation inhibitor combined with a senescence activated β-galactosidase prodrug to selectively target cancer cells
por: Ni, Shuaishuai, et al.
Publicado: (2022)

Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
por: Li, Xuejiao, et al.
Publicado: (2018)

Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy
por: Yang, Jincheng, et al.
Publicado: (2018)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
por: Dickson, Benjamin D., et al.
Publicado: (2019)

In vitro radiosensitization of breast cancer with hypoxia‐activated prodrugs
por: Aiyappa‐Maudsley, Radhika, et al.
Publicado: (2022)

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma
por: Liu, Shujing, et al.
Publicado: (2017)

Phospholipid prodrug conjugates of insoluble chemotherapeutic agents for ultrasound targeted drug delivery
por: Márquez, Mendi G., et al.
Publicado: (2020)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data.
por: Baxter, L. T., et al.
Publicado: (1996)

Prodrugs for Amines
por: Simplício, Ana L., et al.
Publicado: (2008)

Antiparkinson Prodrugs
por: Di Stefano, Antonio, et al.
Publicado: (2008)

Dendrimer Prodrugs
por: da Silva Santos, Soraya, et al.
Publicado: (2016)

Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies
por: Dickopf, Steffen, et al.
Publicado: (2022)

Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years
por: Najjar, Anas, et al.
Publicado: (2020)

Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications
por: Banerjee, Shashwat S., et al.
Publicado: (2012)

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
por: Phillips, Roger M.
Publicado: (2016)

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
por: Hunter, Francis W, et al.
Publicado: (2016)

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

Hypoxia-Activated Albumin-Binding Exatecan Prodrug for Cancer Therapy
por: Cheng, Zhiyang, et al.
Publicado: (2021)

The ProTide Prodrug Technology: From the Concept to the Clinic: Miniperspective
por: Mehellou, Youcef, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9s28oak2sd39obrpkedjvvud9k